With regard to the subsequent AUGMENT-102 trial, which investigated revumenib in combination with FLA in the R/R setting, an interesting issue is that it included patients with NUP98-rearranged AML, highlighting the pivotal and transversal role of the HOXA-MEIS1 axis in leukemogenesis as a key oncogenic driver across multiple AML subtypes. The gene discussed is MEIS1; the disease is acute myeloid leukemia.